A detailed history of Avestar Capital, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Avestar Capital, LLC holds 3,052 shares of VRTX stock, worth $1.53 Million. This represents 0.15% of its overall portfolio holdings.

Number of Shares
3,052
Previous 2,904 5.1%
Holding current value
$1.53 Million
Previous $1.21 Million 17.89%
% of portfolio
0.15%
Previous 0.13%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 08, 2024

BUY
$392.81 - $485.53 $58,135 - $71,858
148 Added 5.1%
3,052 $1.43 Million
Q1 2024

May 10, 2024

BUY
$407.69 - $446.08 $282,936 - $309,579
694 Added 31.4%
2,904 $1.21 Million
Q4 2023

Feb 12, 2024

BUY
$343.0 - $410.68 $81,291 - $97,331
237 Added 12.01%
2,210 $899,000
Q3 2023

Oct 20, 2023

BUY
$338.18 - $362.46 $7,778 - $8,336
23 Added 1.18%
1,973 $686,000
Q2 2023

Aug 01, 2023

SELL
$314.42 - $351.91 $314 - $351
-1 Reduced 0.05%
1,950 $686,000
Q1 2023

Apr 20, 2023

BUY
$283.23 - $323.1 $178,151 - $203,229
629 Added 47.58%
1,951 $614,000
Q4 2022

Jan 20, 2023

SELL
$285.76 - $321.48 $18,002 - $20,253
-63 Reduced 4.55%
1,322 $0
Q3 2022

Oct 26, 2022

SELL
$273.83 - $305.53 $87,351 - $97,464
-319 Reduced 18.72%
1,385 $401,000
Q2 2022

Jul 28, 2022

SELL
$234.96 - $292.55 $1.11 Million - $1.38 Million
-4,711 Reduced 73.44%
1,704 $480,000
Q1 2022

Apr 26, 2022

BUY
$221.42 - $260.97 $1.08 Million - $1.28 Million
4,886 Added 319.56%
6,415 $1.67 Million
Q4 2021

Feb 01, 2022

SELL
$177.01 - $223.45 $17,346 - $21,898
-98 Reduced 6.02%
1,529 $336,000
Q3 2021

Nov 09, 2021

BUY
$181.39 - $202.99 $23,217 - $25,982
128 Added 8.54%
1,627 $295,000
Q2 2021

Aug 03, 2021

BUY
$187.49 - $221.1 $38,810 - $45,767
207 Added 16.02%
1,499 $302,000
Q1 2021

May 03, 2021

BUY
$207.02 - $241.31 $19,045 - $22,200
92 Added 7.67%
1,292 $276,000
Q4 2020

Feb 01, 2021

BUY
$207.01 - $276.09 $38,710 - $51,628
187 Added 18.46%
1,200 $284,000
Q3 2020

Oct 29, 2020

BUY
$255.65 - $303.1 $56,243 - $66,682
220 Added 27.74%
1,013 $210,000
Q2 2020

Jul 29, 2020

BUY
$225.48 - $295.8 $178,805 - $234,569
793 New
793 $230,000
Q3 2019

Nov 14, 2019

SELL
$166.23 - $187.09 $112,039 - $126,098
-674 Closed
0 $0
Q2 2019

Aug 06, 2019

BUY
$164.61 - $190.37 $18,765 - $21,702
114 Added 20.36%
674 $107,000
Q1 2019

May 09, 2019

SELL
$163.73 - $194.7 $8,186 - $9,735
-50 Reduced 8.2%
560 $86,000
Q4 2018

Jan 25, 2019

SELL
$151.91 - $192.21 $8,355 - $10,571
-55 Reduced 8.27%
610 $75,000
Q3 2018

Oct 23, 2018

BUY
$167.73 - $192.74 $6,373 - $7,324
38 Added 6.06%
665 $107,000
Q2 2018

Aug 10, 2018

BUY
$145.72 - $169.96 $22,295 - $26,003
153 Added 32.28%
627 $91,000
Q1 2018

May 10, 2018

BUY
$151.6 - $177.13 $9,550 - $11,159
63 Added 15.33%
474 $57,000
Q4 2017

Feb 14, 2018

BUY
$137.28 - $155.55 $56,422 - $63,931
411
411 $45,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Avestar Capital, LLC Portfolio

Follow Avestar Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Avestar Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Avestar Capital, LLC with notifications on news.